Cerebral Gigantism |
|
|
Clinical Trial: Botulinum Toxin (BOTOX) for Cerebral Palsy
This study is no longer recruiting patients.
|
Purpose
This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children. Botulinum toxin is a naturally occurring bacterial toxin (botulinum toxin) that inactivates certain parts of muscles.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cerebral Palsy Muscle Spasticity | Drug: Botulinum toxin type A | Phase II |
MedlinePlus related topics: Cerebral Palsy; Neuromuscular Disorders
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Botulinum Toxin for Spasticity in Cerebral Palsy
Expected Total Enrollment: 40
Study start: July 1997; Study completion: June 2002
This trial will test the effectiveness of BTX injections versus placebo to reduce plantar-flexor spasticity and improve function and mobility in children with spastic diplegia, a common form of cerebral palsy. The study will evaluate the effects of the treatment across five domains that relate to disability: pathophysiology, impairment, functional limitation, disability, and societal limitation.
Forty children, ages 4 to 12 years, will be recruited and randomized into one of two groups. Group A will receive BTX. Group B will receive a placebo injection. Participants will be assessed at the beginning of the trial and at Weeks 3, 8, 12, and 24. Assessments include quantitative electromyographic kinesiology measurements, electromechanical measurement of joint torque across the ankle joint using the Spasticity Measurement System, Gross Motor Function Measure, physical exam parameters, energy expenditure using the Energy Cost Index, kinematic gait analysis, and the Canadian Occupational Performance Measure.
Participants are followed for a total of 6 months. Participants initially randomized to Group B will have the opportunity for BTX treatment after 24 weeks.
Eligibility
Ages Eligible for Study: 3 Years - 12 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Spastic diplegic cerebral palsy
- Community or independent ambulators
- Expressive communication skills at age 3 or above
- Stable social environment
- Reasonable proximity to the medical center
- Physical therapy at least once per week
- No other serious health problems that would interfere with the study
Exclusion Criteria:
- Other forms of cerebral palsy
- Previous treatment with botulinum toxin
- Musculoskeletal contractures greater than 15 degrees
- Unstable social environment
Location Information
Washington
Children's Hospital and Regional Medical Center, Seattle, Washington, 98105, United States
Ross M. Hays, M.D., Principal Investigator, Children's Hospital and Regional Medical Center
More Information
Record last reviewed: October 2004
Last Updated: October 13, 2004
Record first received: May 16, 2003
ClinicalTrials.gov Identifier: NCT00060957
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Cerebral Gigantism (National Institute of Neurological Disorders and Stroke)

Not Signed In -

